Stephen Z Levine1, Stefan Leucht2. 1. Department of Community Mental Health, University of Haifa, Israel. Electronic address: slevine@univ.haifa.ac.il. 2. Department of Psychiatry and Psychotherapy, Technische Universität München, Klinikum Rechts der Isar, Ismaningerstr. 22, 81675 Muenchen, Germany.
Abstract
BACKGROUND: Reasons for the recent mixed success of research into negative symptoms may be informed by conceptualizing negative symptoms as a system that is identifiable from network analysis. We aimed to identify: (I) negative symptom systems; (I) central negative symptoms within each system; and (III) differences between the systems, based on network analysis of negative symptoms for baseline, endpoint and change. METHODS: Patients with chronic schizophrenia and predominant negative symptoms participated in three clinical trials that compared placebo and amisulpride to 60days (n=487). Networks analyses were computed from the Scale for the Assessment of Negative Symptoms (SANS) scores for baseline and endpoint for severity, and estimated change based on mixed models. Central symptoms to each network were identified. The networks were contrasted for connectivity with permutation tests. RESULTS: Network analysis showed that the baseline and endpoint symptom severity systems formed symptom groups of Affect, Poor responsiveness, Lack of interest, and Apathy-inattentiveness. The baseline and endpoint networks did not significantly differ in terms of connectivity, but both significantly (P<0.05) differed to the change network. In the change network the apathy-inattentiveness symptom group split into three other groups. The most central symptoms were Decreased Spontaneous Movements at baseline and endpoint, and Poverty of Speech for estimated change. CONCLUSIONS: Results provide preliminary evidence for: (I) a replicable negative symptom severity system; and (II) symptoms with high centrality (e.g., Decreased Spontaneous Movement), that may be future treatment targets following replication to ensure the curent results generalize to other samples.
BACKGROUND: Reasons for the recent mixed success of research into negative symptoms may be informed by conceptualizing negative symptoms as a system that is identifiable from network analysis. We aimed to identify: (I) negative symptom systems; (I) central negative symptoms within each system; and (III) differences between the systems, based on network analysis of negative symptoms for baseline, endpoint and change. METHODS:Patients with chronic schizophrenia and predominant negative symptoms participated in three clinical trials that compared placebo and amisulpride to 60days (n=487). Networks analyses were computed from the Scale for the Assessment of Negative Symptoms (SANS) scores for baseline and endpoint for severity, and estimated change based on mixed models. Central symptoms to each network were identified. The networks were contrasted for connectivity with permutation tests. RESULTS: Network analysis showed that the baseline and endpoint symptom severity systems formed symptom groups of Affect, Poor responsiveness, Lack of interest, and Apathy-inattentiveness. The baseline and endpoint networks did not significantly differ in terms of connectivity, but both significantly (P<0.05) differed to the change network. In the change network the apathy-inattentiveness symptom group split into three other groups. The most central symptoms were Decreased Spontaneous Movements at baseline and endpoint, and Poverty of Speech for estimated change. CONCLUSIONS: Results provide preliminary evidence for: (I) a replicable negative symptom severity system; and (II) symptoms with high centrality (e.g., Decreased Spontaneous Movement), that may be future treatment targets following replication to ensure the curent results generalize to other samples.
Authors: Eduardo Fonseca-Pedrero; Javier Ortuño; Martin Debbané; Raymond C K Chan; David Cicero; Lisa C Zhang; Colleen Brenner; Emma Barkus; Richard J Linscott; Thomas Kwapil; Neus Barrantes-Vidal; Alex Cohen; Adrian Raine; Michael T Compton; Erin B Tone; Julie Suhr; Felix Inchausti; Julio Bobes; Axit Fumero; Stella Giakoumaki; Ioannis Tsaousis; Antonio Preti; Michael Chmielewski; Julien Laloyaux; Anwar Mechri; Mohamed Aymen Lahmar; Viviana Wuthrich; Frank Larøi; Johanna C Badcock; Assen Jablensky; Adela M Isvoranu; Sacha Epskamp; Eiko I Fried Journal: Schizophr Bull Date: 2018-10-15 Impact factor: 9.306
Authors: Han-Xue Yang; Hui-Xin Hu; Yi-Jing Zhang; Yi Wang; Simon S Y Lui; Raymond C K Chan Journal: Eur Arch Psychiatry Clin Neurosci Date: 2021-05-13 Impact factor: 5.270
Authors: Juan F Rodríguez-Testal; Salvador Perona-Garcelán; Sonia Dollfus; María Valdés-Díaz; Jesús García-Martínez; Miguel Ruíz-Veguilla; Cristina Senín-Calderón Journal: BMC Psychiatry Date: 2019-10-29 Impact factor: 3.630